CYP2D6 and breast cancer: CYP2D6 IMs and PMs have a higher risk of breast cancer recurrence when treated with tamoxifen (Goetz et al., 2018) and an impaired metabolism has been reported during atomoxetine treatment (Brown et al., 2019).